Deoxypodophyllotoxin Clinical Trials

Size	Price	Qty
1mg	USD 129
5mg	USD 390

Clinical Trials

Several clinical trials are currently actively recruiting across diverse therapeutic areas, investigating acute ischemic stroke involving vascular occlusion, electronic cigarette use and abuse liability, and functional impairments in Parkinson's disease. Across these records, trial phases are categorized as unassigned or not applicable. The studies are sponsored by academic and healthcare institutions, including the Affiliated Hospital of Southwest Medical University, Virginia Commonwealth University alongside the National Institute on Drug Abuse, and Sanko University.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06125236	Recruiting	Acute Ischemic Stroke	Zhengzhou Yuan\|The Affiliated Hospital Of Southwest Medical University	2023-11-09	--
NCT05971823	Recruiting	Electronic Cigarette Use	Virginia Commonwealth University\|National Institute on Drug Abuse (NIDA)	2023-07-31	Not Applicable
NCT06146283	Recruiting	Parkinson Disease	Sanko University	2023-06-01	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Deoxypodophyllotoxin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Deoxypodophyllotoxin binds directly to tubulin heterodimers, inhibiting microtubule polymerization and halting cell cycle progression at the G2/M phase to induce apoptotic cell death. Through its combined antimitotic and anti-inflammatory downstream effects, the compound provides therapeutic potential in attenuating neuroinflammatory injury and cell loss associated with conditions such as acute ischemic stroke and Parkinson's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).